Semax and selank with SNRIs and Adderall

A recurring question in peptide forums is whether semax and selank can be used alongside SNRIs (such as venlafaxine or duloxetine, prescribed for anxiety and depression) and amphetamine salts such as Adderall (prescribed for ADHD). The short answer is that no published interaction study covers any of these combinations, so there is no peer-reviewed safety signal to point to in either direction.^[1] What follows is a plain account of what each compound does on the relevant neurotransmitter systems, where those systems overlap, and what the absence of interaction data actually means.

What semax does in the brain

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone. Rodent work by Dolotov and colleagues (2006, PMID 16635254) found that intranasal administration at 50 and 250 micrograms per kilogram raised brain-derived neurotrophic factor (BDNF) protein in the rat basal forebrain within three hours, with no response in the cerebellum, suggesting regional specificity.^[2] A separate set of experiments by Eremin and colleagues (2005, PMID 16362768) found a 25 percent rise in the striatal serotonin metabolite 5-HIAA two hours after semax injection, and a potentiated dopamine release when semax preceded amphetamine in rats.^[3] Both are rodent pharmacology studies. Semax has no marketing authorisation in the EU, EEA, UK, or US, and no Western-standard randomised controlled trial has been completed in healthy adults.

What selank does in the brain

Selank is a second Russian-developed heptapeptide, structurally a synthetic analogue of the endogenous neuropeptide tuftsin. The mechanistic literature places its anxiolytic action at the GABAergic system. Vyunova and colleagues (2018, PMID 30255741) describe selank as a positive allosteric modulator of GABA receptors, enhancing GABA binding without directly activating the receptor itself, at a site that overlaps only partially with where benzodiazepines bind.^[4] Gene-expression work by Volkova and colleagues (2016, PMID 26924987) found significant changes in 45 genes involved in GABAergic neurotransmission one hour after selank administration in rats.^[5] Like semax, selank has no marketing authorisation outside Russia and no Western-standard RCT in healthy adults.

How SNRIs work

SNRIs (serotonin-norepinephrine reuptake inhibitors) block the serotonin transporter (SERT) and the norepinephrine transporter (NET), raising synaptic levels of both monoamines. A review by Shelton (2019, PMID 30838456) notes that different agents in this class differ in how strongly they hit each transporter: venlafaxine is roughly 30-fold more potent at SERT than at NET at lower doses, whereas duloxetine is closer to a 10:1 ratio.^[6] At any therapeutic dose, an SNRI is holding serotonin transporter occupancy high. That is the relevant starting point when adding anything that also touches the serotonergic system.

How amphetamine (Adderall) works

Amphetamine promotes release of dopamine and norepinephrine from nerve terminals and inhibits their reuptake, raising synaptic monoamine levels in prefrontal and striatal circuits. Because amphetamine also promotes serotonin release, albeit less potently than its dopamine effect, it can add serotonergic load in a system where SERT is already blocked by the SNRI.^[7] A documented case report by Prior and colleagues (2002, PMID 11999244) described serotonin toxicity at therapeutic doses when dexamphetamine was combined with venlafaxine, illustrating that the combination can produce an adverse pharmacodynamic interaction.^[8]

Where semax and selank enter the picture

The Eremin (2005) rodent data showed that semax raised the striatal serotonin metabolite 5-HIAA by 25 percent and potentiated dopamine release when co-administered with amphetamine.^[3] An environment where SERT is already blocked by an SNRI, dopamine is already elevated by amphetamine, and serotonin metabolites are further raised by semax is pharmacologically loaded, even if the absolute magnitude of semax's serotonergic effect in rodents is modest. Whether this translates to a clinically meaningful increment in a human taking a prescribed SNRI and amphetamine is unknown: no study has tested it.

Selank's GABAergic mechanism is more clearly distinct from the serotonin-norepinephrine axis that SNRIs and amphetamine operate on. Medvedev and colleagues (2014, PMID 25176261) observed that selank's anxiolytic effect in 60 patients with phobic-anxiety disorders persisted for about one week after the final dose, with a favourable tolerability profile compared to phenazepam.^[9] A later controlled trial by the same group (PMID 26356395) found that adding selank to phenazepam in 40 patients with anxiety-spectrum disorders reduced benzodiazepine side effects while bringing therapeutic effects on earlier.^[10] Neither study involved co-administration with SNRIs or amphetamine, so these findings describe selank in isolation, not in the combination under discussion.

Why gauging the effect is genuinely difficult on this background

The forum question that prompted this article raises a real methodological problem: if you are already on an SNRI and amphetamine, both of which have substantial effects on mood, cognition, and energy, it is hard to detect whether a grey-market intranasal peptide is doing anything at all. The baseline is moving and the variables are not controlled. The published literature on semax and selank describes their effects in naive subjects or patients with specific conditions. It does not characterise how their mechanisms interact with chronic SERT blockade and sustained dopaminergic stimulation.

What we do not know

The honest summary of the evidence gap is this. There is no published human pharmacology study of semax alongside an SNRI. There is no published human pharmacology study of selank alongside an SNRI or alongside amphetamine. The rodent data on semax raises a reasonable flag about adding a serotonin-modulatory compound on top of an existing SERT-blocking background, particularly when amphetamine is also present. The selank data is more reassuring on the serotonergic front but the GABAergic mechanism has not been characterised in the context of chronic stimulant use. None of this adds up to a published "avoid" signal, but none of it adds up to a documented "safe" signal either. For the regulatory context of either compound see the semax page: neither has a marketing authorisation in the EU, EEA, UK, or US, and both are obtained through grey-market supply chains with no regulated quality control.

Anyone weighing this combination should discuss it with a clinician who knows their full medication list, psychiatric history, and cardiovascular status. That is not a generic disclaimer: the specific combination of amphetamine plus SNRI already carries a documented serotonin-toxicity risk at therapeutic doses, and adding further monoamine-active compounds from an unregulated supply chain compounds the unknowns without any offsetting characterised safety data.